Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…
Switzerland Bairbre Hickie, General Manager at Takeda, discusses the company’s strategic priorities in Switzerland, focusing on its commitment to bringing innovative treatments to patients and its role in advancing the life sciences ecosystem. In this interview, Hickie explores Takeda’s approach to partnerships, its focus on rare diseases and oncology, and how…
Switzerland Nicolas Durand, CEO of Fondation Campus Biotech Geneva, shares insights into the foundation’s unique role as a catalyst for neuroscience and digital health innovation in Switzerland. In this interview, Durand discusses the foundation’s collaborative model, the importance of building critical mass in a specialised domain, and how Fondation Campus Biotech…
Switzerland Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this interview, Nasri discusses Biopôle’s key priorities, including the integration of AI and data, sustainability in life sciences, and the importance…
Switzerland Oliver Kuhn, CEO of Selectchemie, has had a diverse career spanning various sectors, starting in the financial industry before transitioning to healthcare. Under his leadership, Selectchemie has sharpened its strong focus on high-quality APIs, excipients, as well as own dossiers and finished-dose-formulations, setting itself apart through a tailored service that…
Switzerland Once a traditional Swiss pharmaceutical wholesaler, Unipharma has undergone a profound transformation into a globally oriented, strategy-driven partner for hospitals, pharmaceutical, and biotechnology companies. Under the leadership of CEO Simone Maisto, the company has redefined its business model, streamlined its portfolio around high-value therapies, and expanded into emerging markets, all…
Switzerland Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition. From navigating a near-collapse to redefining the company’s role…
Switzerland SkyCell is at the forefront of a fundamental shift in pharmaceutical logistics, where AI, real-time monitoring, and sustainability are no longer optional but essential. As pharmaceutical supply chains grow more complex, the need for precision, resilience, and carbon-conscious innovation has never been greater. With AI-driven optimization redefining efficiency and risk…
Global Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With bold investments in R&D and AI-driven innovation, the French pharma is positioning itself as a pure-play biopharma leader. In conversation…
Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…
Europe The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health. CEO pro-bono Dr Antonella Santuccione Chadha comments on the organisation’s newly extended global reach, progress in understanding the link between…
Switzerland The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to antimicrobial medicines (including antibiotics, antivirals, antifungals and antiparasitics). This makes infections harder to treat…
See our Cookie Privacy Policy Here
